Evaluation of IL 12B Genetic Polymorphism (rs3213094)

Sponsor
South Valley University
Study ID
NCT07128472
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • Humira — DRUG
    Assess the response of psoriasis and psoriatic arthritis to Humira and also Assessing the pharmacogenetic association between IL 12B genetic polymorphism (rs3213094) in psoriatic and psoriatic arthritis patients taking Humira.

Study Details

Psoriasis is a skin disorder that is chronic proliferative and inflammatory in nature. Extensor surfaces, scalp, and lumbosacral area are covered in erythematous plaques with silvery scales. The disease can also impair the eyes and joints. It has no cure. Because of their low quality of life, many psoriasis patients experience depression. In addition to the cutaneous manifestations, it is associated with an increased risk of psoriatic arthritis, depression and cardiovascular disease.

Key Dates

Start date
Aug 1, 2025
Status verified
Aug 2025
Primary completion
Jan 20, 2026
Completion
Feb 1, 2026

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Patients Group
    About 20 patients with psoriasis and psoriatic arthritis.
  • Active Comparator: Healthy Group
    About 20 healthy control group.

Primary Outcome Measure

Treatment of Psoriasis and Psoriatic Arthritis [ Time Frame: 3 Months ]

Central Contacts

Related Studies